• Temporal patterns of bowel and bladder toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones prostate cancer.[ICORG 97-01]

      Barry, A.; Lyons, C.; Dunne, M.; Thirion, P.; Armstrong, J.; St. Luke's Radiation Oncology Network (2011-10)
      Poster presentation - ASTRO annual meeting, Florida, October, 2011.
    • Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).

      Walsh, Lorraine; Gillham, Charles; Dunne, Mary; Fraser, Ian; Hollywood, Donal; Armstrong, John; Thirion, Pierre; Department of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland. (Elsevier, 2011-01)
      We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications.
    • Transdermal hyoscine induced unilateral mydriasis.

      Hannon, Breffni; Jennings, Valerie; Twomey, Marie; O'Reilly, Maeve; Palliative Medicine Department, Our Lady's Children's Hospital, Dublin, Ireland. breffnilhannon@yahoo.co.uk (2012-03-20)
      The authors present a case of unilateral mydriasis in a teenager prescribed transdermal hyoscine hydrobromide (scopolamine) for chemotherapy induced nausea and vomiting. The authors discuss the ocular side-effects associated with this particular drug and delivery system and the potential use of transdermal hyoscine as an antiemetic agent in this group.
    • An unusual case of dyspnea in metastatic breast carcinoma.

      Cronin, Kathleen Ann; Twomey, Marie; O'Reilly, Maeve; Carney, Desmond N (Elsevier, 2011-02)
    • An Unusual Case of Marginal Zone B-Cell Lymphoma Arising in the Breast - Its Diagnosis and the Role of Radiotherapy in its Management.

      Rock, Kathy; Rangaswamy, Guhan; O'Sullivan, Siobhra; Coffey, Jerome; Department of Radiation Oncology, St. Luke's Hospital, Rathgar, Dublin 6, Ireland. (Karger, 2011-10)
      BACKGROUND: Primary lymphoma of the breast accounts for 0.04-0.5% of all breast malignancies and approximately 1% of all extranodal lymphomas. For stage IE node-negative disease, involved field radiotherapy is recommended except for very young women in whom the risk of breast cancer is a concern. The rate of complete response for limited stage extranodal marginal B-cell lymphoma is in excess of 90%. CASE REPORT: We report the case of a 62-year-old lady who presented with a unilateral painless palpable right breast lump. She subsequently underwent a trucut biopsy of the lesion. The histology revealed a low-grade B-cell non-Hodgkin's lymphoma (NHL). Immunohistochemistry showed that more than 95% of the cells were B cells which were CD 20+/CD 45+ and BC L6+. This confirmed the diagnosis of marginal zone lymphoma. Staging work-up was negative for distant metastases. Serum alkaline phosphatase and lactate dehydrogenase were normal. The patient had no 'B' symptoms. Her final diagnosis was clinical stage IAE NHL, and she was referred for curative radiotherapy. CONCLUSION: Radiation treatment is a safe and extremely effective modality of treatment for early stage I marginal zone B-cell lymphomas of the breast.
    • An Unusual Case of Marginal Zone B-Cell Lymphoma Arising in the Breast – Its Diagnosis and the Role of Radiotherapy in its Management

      Rock, Kathy; Rangaswamy, G; O'Sullivan, S.; Coffey, J.; Department of Radiation Oncology, St. Luke’s Hospital, Rathgar, Dublin 6, Ireland (Karger, 2011)
    • The use of complementary and alternative medicine by Irish pediatric cancer patients.

      O'Connor, Niamh; Graham, Donna; O'Meara, Anne; Devins, Mary; Jennings, Valerie; O'Leary, Denise; O'Reilly, Maeve; The Departments of Palliative Medicine and Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland. (2013-10)
      The use of complementary and alternative medicine (CAM) in the Irish pediatric cancer setting has not previously been established.